Halo Pharma in connection with its sale to Cambrex for approximately US$425 million

On July 23, 2018, Cambrex Corporation announced that it has entered into a definitive agreement to acquire Halo Pharma for approximately US$425 million.

With the acquisition of Halo, Cambrex will enter the large and growing finished dosage form Contract Development and Manufacturing Organization (CDMO) market.

Halo is a leading dosage form CDMO and provides drug product development and commercial manufacturing services, specializing in oral solids, liquids, creams, sterile and non-sterile ointments. Halo’s core competencies include developing and manufacturing highly complex and difficult to produce formulations, products for pediatric indications and controlled substances.

Cambrex is an innovative life sciences company and a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs).

Osler, Hoskin & Harcourt LLP represented Halo as its Canadian counsel with a team consisting of Randall Pratt, Amelia Miao (Corporate), Greg Wylie (Tax), and Mark Austin (Life Sciences).